Flu vaccine strategy on the line as new US leaders anticipated to take charge
As countries in the Northern hemisphere deal with the flu season, experts say regulation surrounding flu vaccines could be due…
Featured
-
-
How Pfizer management outplayed activist investor Starboard
Amidst dwindling share prices and widespread criticism, Pfizer CEO Albert Bourla appears to have withstood an attempted ousting by activist…
-
New study finds obesity costs US industry $347bn a year
A new study published in Nature Nutrition & Diabetes estimates the economic burden associated with obesity on major US industries…
-
PrEP therapies offer new hope in HIV preventive landscape as vaccine failures amass
Research activity in the human immunodeficiency viruses space (HIV) is pivoting towards pre-exposure prophylaxis (PrEP) therapies as vaccine failures rack…
-
Worldwide 2024 elections pose pivotal shifts in life sciences and healthcare
The outcomes of this year’s US, EU, and UK elections and their downstream effects will lead to drastic changes to…
-
Are dry powder inhalers the key to sustainable respiratory care?
In a bid to improve the pharma sector’s drive to cut down greenhouse emissions, several companies are advancing dry powder…
-
How to adapt to choppy waters in biotech ecosystem
As the US enters a new political era, experts predict that the pharmaceutical and clinical trials industry will have to…
-
Investment surges, hurdles and emerging innovations in neuroscience
Innovation in neuropsychiatry has been dormant for nearly forty years, said Kabir Nath, CEO, Compass Pathways in a panel discussion…
-
Minister for Science champions partnerships with private clinical sector in UK
Lord Patrick Vallance has emphasised plans for a close collaboration between the government and private sector, in line with the…
-
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA
Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like…
